AtriCure (ATRC) Gains China Approval for AtriClip LAA System

AtriCure, Inc. (ATRC) recently announced receipt of regulatory approval from China’s National Medical Products Administration (NMPA) for its AtriClip Left Atrial Appendage (LAA) Exclusion System. This approval will enable AtriCure to market and sell several models of the AtriClip device in China, expanding access to its life-saving cardiac solutions.AtriCure has leading technologies for the treatment of atrial fibrillation (Afib) and related conditions, which affect over 37 million people globally. Electrop ...